

Date: 14th April 2022

By Email

Shri. Kamlesh Kumar Pant Chairman National Pharmaceuticals Pricing Authority Department of Pharmaceuticals Ministry of Chemicals & Fertilizers Government of India

Subject: OPPI's submission to NPPA - Information regarding Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Dear Sir,

Greetings from the Organisation of Pharmaceuticals Producers of India (OPPI).

We are writing to you in the context of Clause 8.3 of the voluntary UCPMP that requires all the associations to send a quarterly report of the complaints received and decisions taken by the complaint handling bodies set up by such associations to National Pharmaceutical Pricing Authority (NPPA).

As a requirement under UCPMP, we wish to report to you that **no complaints were received by OPPI for the last two years i.e., from the period 1**st **April 2020 till 31**st **March 2022**.

As requested, we submit the following:

- a) Details of all the Complaints received and the disposal including the manner in which they were disposed since inception of the code, in a tabular manner.
 - No complaints were received by OPPI for the last two years i.e., from the period 1st April 2020 till 31st March 2022.

b) Whether, currently, the ECPMP is in place and share the details of the ECPMP members.

- Yes, we have formed ECPMP committee since 30th September 2020 and have uploaded the committee members details onto our website.
- OPPI website https://www.indiaoppi.com/who-we-are/ For Filing Complaints under the OPPI Code of Pharmaceutical Practices 2019 and to view the list of ECPMP & AECPMP committee membersClick here
- c) Whether there is any portal or online mechanism to receive the complaints by ECPMP and dispose the same with a communication to the complainant.
 - Yes, for filing complaints we have shared our email id as admin@indiaoppi.com
 - OPPI website <u>https://www.indiaoppi.com/who-we-are/</u>

Organisation of Pharmaceutical Producers of India



For Filing Complaints under the OPPI Code of Pharmaceutical Practices 2019 and to view the list of ECPMP & AECPMP committee membersClick here

- d) If so, pl share the link of the portal, that belongs to the Association.
 - OPPI website https://www.indiaoppi.com/who-we-are/
- e) Whether, currently, the AECPMP is in place and share the details of the ECMPM members
 - Yes, we have formed AECPMP committee since 30th September 2020 and have uploaded the committee members details in our website
 - OPPI website <u>https://www.indiaoppi.com/who-we-are/</u>
 For Filing Complaints under the OPPI Code of Pharmaceutical Practices 2019 and to view the list of ECPMP & AECPMP committee membersClick here

We have been regularly submitting quarterly report to the Department of Pharmaceuticals since April 2020. The Reports are attached hereto.

OPPI and its member companies remain committed to abide by compliance and ethical business practices while providing quality medicines to the patients in India.

Yours sincerely

Regards,

K G Ananthakrishnan Director General



Proforma for furnishing quarterly return on complaints received and action thereafter by industries Association as per para (8) of UCPMP code.

Quarterly period: January 2022, February 2022 & March 2022

1	Name of Association	Organisation of Pharmaceutical Producers of India (OPPI)
2	Date of uploading UCPMP along with detail procedure on website of association	20 th August 2020
3	Whether the committees viz ECPMP & AECPMP have been formed	Yes
	i. if yes (mention date)	30 th September 2020
	ii. if not, reason thereof	
	iii. Likely Date of Formation	
4	No. of complaint received during the quarter ending March, 2022	None
	No. of complaint disposed off during the quarter ending March, 2022	Not Applicable (NA)
	Details of the complaint & decision thereon on each complaint	N.A
5	No. of appeal received during the quarter ending March, 2022	None
	No. of appeal disposed off during the quarter ending March, 2022	N.A
	Details of appeal & decision thereon for each appeal	N.A
6	Submission of quarterly report to NPPA	 Submitted to NPPA on 8th April 2022
		 We have been sharing quarterly reports from 2020 with the Department of Pharmaceutical (DoP)

Authorised Signatory: Name: K G Ananthakrishnan Designation: Director General